Atara Biotherapeutics Inc (ATRA) Expected to Announce Earnings of -$1.18 Per Share

Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post ($1.18) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.18) to ($1.17). Atara Biotherapeutics posted earnings per share of ($1.02) during the same quarter last year, which indicates a negative year over year growth rate of 15.7%. The business is expected to report its next earnings results on Thursday, November 8th.

On average, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.58) per share for the current financial year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts expect that the company will report earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.17).

A number of equities research analysts recently weighed in on the company. BidaskClub cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price target on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Atara Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $47.80.

ATRA stock traded down $2.38 during midday trading on Friday, reaching $35.77. 9,642 shares of the company’s stock traded hands, compared to its average volume of 716,928. Atara Biotherapeutics has a 1-year low of $12.65 and a 1-year high of $54.45. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -9.40 and a beta of 2.54.

In other Atara Biotherapeutics news, EVP Christopher Haqq sold 775 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now directly owns 331,355 shares in the company, valued at approximately $12,439,066.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joe Newell sold 10,000 shares of the stock in a transaction on Monday, July 30th. The shares were sold at an average price of $35.78, for a total value of $357,800.00. Following the completion of the transaction, the insider now owns 41,858 shares in the company, valued at $1,497,679.24. The disclosure for this sale can be found here. Insiders have sold a total of 93,575 shares of company stock valued at $3,633,158 over the last ninety days. Insiders own 10.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRA. BlackRock Inc. boosted its position in Atara Biotherapeutics by 45.0% in the 1st quarter. BlackRock Inc. now owns 2,844,441 shares of the biotechnology company’s stock valued at $110,934,000 after buying an additional 882,180 shares during the last quarter. PointState Capital LP bought a new position in Atara Biotherapeutics in the 1st quarter valued at $11,583,000. Northern Trust Corp boosted its position in Atara Biotherapeutics by 27.1% in the 2nd quarter. Northern Trust Corp now owns 497,371 shares of the biotechnology company’s stock valued at $18,278,000 after buying an additional 105,935 shares during the last quarter. UBS Group AG boosted its position in Atara Biotherapeutics by 7,970.1% in the 1st quarter. UBS Group AG now owns 102,974 shares of the biotechnology company’s stock valued at $4,016,000 after buying an additional 101,698 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Atara Biotherapeutics by 73.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 237,668 shares of the biotechnology company’s stock valued at $8,734,000 after buying an additional 100,432 shares during the last quarter.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply